2C protein of Enterovirus: key protein of viral replication and antiviral target.


Journal

Virologie (Montrouge, France)
ISSN: 1267-8694
Titre abrégé: Virologie (Montrouge)
Pays: France
ID NLM: 9802575

Informations de publication

Date de publication:
01 06 2023
Historique:
medline: 24 7 2023
pubmed: 21 7 2023
entrez: 21 7 2023
Statut: ppublish

Résumé

Enteroviruses (EVs) include many human pathogens of increasing public health concern. These EVs are often associated with mild clinical manifestations, but they can lead to serious complications such as encephalitis, meningitis, pneumonia, myocarditis or poliomyelitis. Despite significant advances, there is no approved antiviral therapy for the treatment of enterovirus infections. Due to the high genotypic diversity of EVs, molecules targeting highly conserved viral proteins may be considered for developing a pan-EV treatment. In this regard, the ATPase/Helicase 2C, which is a highly conserved non-structural protein among EVs, has essential functions for viral replication and is therefore an attractive antiviral target. Recent functional and structural studies on the 2C protein led to the identification of molecules showing ex vivo anti-EV activity and associated with resistance mutations on the coding sequence of the 2C protein. This review presents the current state of knowledge about the 2C protein from an antiviral target perspective and the mode of action of specific inhibitors for this therapeutic target.

Identifiants

pubmed: 37476987
pii: vir.2023.1002
doi: 10.1684/vir.2023.1002
doi:

Substances chimiques

Antiviral Agents 0
Antigens, Viral 0

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

35-49

Auteurs

Priscila El Kazzi (P)

AFMB, CNRS UMR 7257, Aix-Marseille Université, Case 925, 163 av. de Luminy, 13288 Marseille cedex 09, France.

Carole Yaacoub (C)

Unité des Virus émergents (UVE), Aix-Marseille Université, IRD 190,Inserm 1207, Marseille, France, Laboratory of Applied Biotechnology (LBA3B), Azm Center for Research in Biotechnology and its Applications, EDST, Lebanese University, Tripoli 1300, Lebanon.

Ziad Fajloun (Z)

Laboratory of Applied Biotechnology (LBA3B), Azm Center for Research in Biotechnology and its Applications, EDST, Lebanese University, Tripoli 1300, Lebanon, Department of Biology, Faculty of Sciences 3, Lebanese University, Michel Slayman Tripoli Campus Ras Maska, Tripoli 1352, Lebanon.

Patrice Vanelle (P)

Aix-Marseille Université, CNRS, Institut de Chimie radicalaire (ICR) UMR7273, Équipe Pharmaco-chimie radicalaire, Faculté de Pharmacie, 27 bld Jean Moulin, CS30064, 13385 Marseille cedex 05, France.

Etienne Decoly (E)

AFMB, CNRS UMR 7257, Aix-Marseille Université, Case 925, 163 av. de Luminy, 13288 Marseille cedex 09, France.

Bruno Coutard (B)

Unité des Virus émergents (UVE), Aix-Marseille Université, IRD 190,Inserm 1207, Marseille, France.

Karine Barral (K)

Aix-Marseille Université, CNRS, Institut de Chimie radicalaire (ICR) UMR7273, Équipe Pharmaco-chimie radicalaire, Faculté de Pharmacie, 27 bld Jean Moulin, CS30064, 13385 Marseille cedex 05, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH